Last reviewed · How we verify
MR or M-M-R II ® vaccine
M-M-R II is a live attenuated vaccine that stimulates immune response against measles, mumps, and rubella viruses.
M-M-R II is a live attenuated vaccine that stimulates immune response against measles, mumps, and rubella viruses. Used for Prevention of measles, mumps, and rubella in children and adults.
At a glance
| Generic name | MR or M-M-R II ® vaccine |
|---|---|
| Also known as | Merck |
| Sponsor | Washington University School of Medicine |
| Drug class | Live attenuated vaccine |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains weakened (attenuated) strains of measles, mumps, and rubella viruses that trigger both humoral and cell-mediated immune responses without causing disease. Upon vaccination, the immune system produces antibodies and memory cells against these three viral pathogens, providing long-term protection against natural infection.
Approved indications
- Prevention of measles, mumps, and rubella in children and adults
Common side effects
- Fever
- Rash
- Local injection site reactions (pain, erythema, swelling)
- Parotitis
- Arthralgia or arthritis
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MR or M-M-R II ® vaccine CI brief — competitive landscape report
- MR or M-M-R II ® vaccine updates RSS · CI watch RSS
- Washington University School of Medicine portfolio CI